Unknown

Dataset Information

0

Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.


ABSTRACT: Follistatin, a physiological inhibitor of myostatin, induces a dramatic increase in skeletal muscle mass, requiring the type 1 IGF-I receptor/Akt/mTOR pathway. The aim of the present study was to investigate the role of IGF-I and insulin, two ligands of the IGF-I receptor, in the follistatin hypertrophic action on skeletal muscle. In a first step, we showed that follistatin increases muscle mass while being associated with a downregulation of muscle IGF-I expression. In addition, follistatin retained its full hypertrophic effect toward muscle in hypophysectomized animals despite very low concentrations of circulating and muscle IGF-I. Furthermore, follistatin did not increase muscle sensitivity to IGF-I in stimulating phosphorylation of Akt but, surprisingly, decreased it once hypertrophy was present. Taken together, these observations indicate that increased muscle IGF-I production or sensitivity does not contribute to the muscle hypertrophy caused by follistatin. Unlike low IGF-I, low insulin, as obtained by streptozotocin injection, attenuated the hypertrophic action of follistatin on skeletal muscle. Moreover, the full anabolic response to follistatin was restored in this condition by insulin but also by IGF-I infusion. Therefore, follistatin-induced muscle hypertrophy requires the activation of the insulin/IGF-I pathway by either insulin or IGF-I. When insulin or IGF-I alone is missing, follistatin retains its full anabolic effect, but when both are deficient, as in streptozotocin-treated animals, follistatin fails to stimulate muscle growth.

SUBMITTER: Barbe C 

PROVIDER: S-EPMC4572457 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Role of IGF-I in follistatin-induced skeletal muscle hypertrophy.

Barbé Caroline C   Kalista Stéphanie S   Loumaye Audrey A   Ritvos Olli O   Lause Pascale P   Ferracin Benjamin B   Thissen Jean-Paul JP  

American journal of physiology. Endocrinology and metabolism 20150728 6


Follistatin, a physiological inhibitor of myostatin, induces a dramatic increase in skeletal muscle mass, requiring the type 1 IGF-I receptor/Akt/mTOR pathway. The aim of the present study was to investigate the role of IGF-I and insulin, two ligands of the IGF-I receptor, in the follistatin hypertrophic action on skeletal muscle. In a first step, we showed that follistatin increases muscle mass while being associated with a downregulation of muscle IGF-I expression. In addition, follistatin ret  ...[more]

Similar Datasets

| S-EPMC7663972 | biostudies-literature
2017-08-17 | PXD005899 | Pride
| S-EPMC7876046 | biostudies-literature
| S-EPMC3384410 | biostudies-literature
| S-EPMC544037 | biostudies-literature
2020-05-14 | GSE150464 | GEO
| S-EPMC6684588 | biostudies-literature
| S-EPMC5394462 | biostudies-literature
| S-EPMC5401943 | biostudies-literature
| S-EPMC3520615 | biostudies-literature